glp-1/fgf21 agonist boehringer GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Glucagon, GLP-1 and Thermogenesis
Description
161 The results of the Phase II clinical trials of retatrutide were published in The Lancet in 2023

[DOI] [PubMed] [Google Scholar] 661.Gutzwiller J.P., Tschopp S., Bock A., Zehnder C.E., Huber A.R., Kreyenbuehl M

Honda K, Littman DR

Affected individuals are encouraged to contact King Law to discuss whether they meet the criteria to take legal action
The high global prevalence of type 2 diabetes continues to drive the demand for effective glucose-lowering agents like GLP-1 receptor agonists

Direct head-to-head comparison of efficacy between the two medications cannot be made from these separate trials
